Syntara Limited is a clinical-stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.
Price delay between 20-60 minutes.
Researchers at Heidelberg University to take SNT-5505 into the clinic for the blood cancers myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML)…
CEO Gary Phillips speaks with JustStocks following the news we have completed full recruitment of our Phase 2 trial evaluating SNT-5055 in…
Syntara has completed full recruitment in its Phase 2 trial evaluating SNT-5055, in combination with ruxolitinib, treating the bone marrow cancer myelofibrosis.…
Syntara receives firm commitments to raise approximately A$5.0 million via a two-tranche placement at A$0.028 per share. Funds raised to provide certainty…
Syntara has reached the 50% recruitment milestone in its Phase 2 trial evaluating SNT-5505, in combination with ruxolitinib, treating the bone marrow…
Syntara has added a new blood cancer indication to the clinical development plans for its drug discovery SNT-5505. The drug will be…
Syntara Limited (ABN 75 082 811 630) is listed on the Australian Securities Exchange, code SNT. Syntara Limited was named Pharmaxis Ltd until 4 December 2023. It’s ASX code was PXS. The Syntara website is current for all investor information from 4 December 2023, with select historical information provided for ease of use. For a complete archive of historical information visit the ASX website.